Chemometec A/S represents strong values and a clear corporate philosophy. The company prioritizes innovation, scientific excellence, and customer satisfaction. With a focus on providing advanced solutions for cell counting and analysis, Chemometec A/S is committed to delivering accurate, reliable, and user-friendly products. They strive to empower researchers and laboratories with cutting-edge technologies that enhance efficiency and productivity. By continuously investing in research and development, Chemometec A/S ensures that their customers have access to the latest advancements in cell analysis. With their commitment to quality and customer-centric approach, Chemometec A/S aims to be a trusted partner in the field of life sciences.

Chemometec A/S is primarily present in several countries and regions worldwide. The company operates in various regions, including Europe, North America, Asia-Pacific, and the Middle East. Some specific countries where Chemometec A/S has a significant presence are Denmark, the United States, China, Germany, India, Japan, and many others. With its global reach, Chemometec A/S aims to serve customers and expand its market presence across different economies.

Some significant milestones achieved by Chemometec A/S include the development and commercialization of their flagship product, the NucleoCounter® system, which revolutionized cell counting and viability analysis in life science research and industry. The company also expanded its product portfolio with the introduction of the NucleoCassette™ and NucleoView™ software, enhancing the efficiency and accuracy of cell analysis further. Chemometec A/S successfully established a global presence, with offices and distributors in key markets worldwide, consolidating its position as a leading provider of innovative solutions for cell analysis. Through continuous investment in research and development, the company continues to deliver groundbreaking technologies to support scientific advancements.

Chemometec A/S is a Danish biotechnology company founded in 1997. With headquarters in Allerød, Denmark, the company specializes in developing and manufacturing innovative instruments and software solutions for cell counting and analysis. Chemometec A/S has established itself as a leading provider of automated cell counters, offering high-quality and reliable products to the global scientific community. The company has garnered significant recognition for its unique imaging technology and advanced image analysis algorithms. Over the years, Chemometec A/S has expanded its product portfolio, ensuring accurate cell counting and viability assessment, particularly in the fields of hematology, microbiology, and life sciences.

The main competitors of Chemometec A/S in the market are Beckman Coulter, Inc., Sysmex Corporation, and Becton, Dickinson and Company.

Chemometec A/S is primarily active in the biotechnology and life sciences industries.

The business model of Chemometec A/S is focused on providing advanced solutions for cellular analysis and diagnostics. The company specializes in developing and manufacturing instruments that enable users to quantify and analyze cells for various purposes, such as cell counting, size measurement, viability assessment, and cell cycle analysis. Chemometec A/S's innovative technologies and products cater to a wide range of industries, including biopharmaceuticals, life sciences research, clinical diagnostics, and industrial manufacturing. With a strong emphasis on accuracy, reliability, and user-friendliness, Chemometec A/S aims to support its customers in improving their research outcomes and diagnostic capabilities.

Chemometec A/S KGV ir 56,73.

Chemometec A/S KUV ir 18,95.

AlleAktien kvalitātes vērtējums Chemometec A/S ir 10/10.

Chemometec A/S apgrozījums ir 407,87 milj. DKK.

Chemometec A/S peļņa ir 136,28 milj. DKK.

Chemometec A/S is a Danish biotech company that offers innovative solutions and products for cell analysis in the fields of Hematology, Oncology, and Stem Cell Research. Their core product is the NucleoCounter platform, which includes automated cell counters with patented technology for precise counting and sizing of cells. The company serves various customers, including research institutions, clinical labs, hospitals, biotech and pharma companies, and contract research organizations. They aim to provide solutions that help customers achieve their scientific and clinical goals faster, more reliably, and at a lower cost.

Chemometec A/S izmaksā dividendes 0 DKK, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Chemometec A/S vai uzņēmums nedod dividendes.

Chemometec A/S ISIN ir DK0060055861.

Chemometec A/S WKN ir A0MS80.

Chemometec A/S simbols ir CHEMM.CO.

Pēdējo 12 mēnešu laikā Chemometec A/S maksāja dividendes 4,00 DKK apmērā. Tas atbilst aptuveni 0,90 % dividendes ražībai. Nākamajos 12 mēnešos Chemometec A/S plāno maksāt dividendes 1,61 DKK apmērā.

Chemometec A/S pašreizējā dividendu rentabilitāte ir 0,90 %.

Chemometec A/S maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos novembris, novembris, novembris, novembris.

Chemometec A/S pēdējo 5 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 1,61 DKK. Tas atbilst dividendes ražībai 0,36 %.

Chemometec A/S tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Chemometec A/S apmērā 4 DKK, kas tika izmaksāta 15.10.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 11.10.2024..

Pēdējās dividendes izmaksa notika 15.10.2024..

Gadā 2023, Chemometec A/S izmaksāja 6 DKK dividendes.

Chemometec A/S dividendes tiek izmaksātas DKK.